Date: 2015-12-14
Type of information: Production agreement
Compound: CMX-02
Company: Complix (Belgium) Selexis (Switzerland)
Therapeutic area: Autoimmune diseases - Cancer - Oncology
Type agreement: manufacturing production
Action mechanism: bispecific antibody/fusion protein/alphabody. CMX-02 is a bispecific Alphabody-antibody fusion protein that simultaneously targets TNFα and IL-23. Complix believes that CMX-02, with its dual activity, can tackle both the upstream cascade initiation as well as the more downstream acute phase of the disease, and, therefore, has the potential to offer major clinical benefits over existing therapies. Alphabodies are a new class of biologicals that have the potential to address a wide range of disease targets, in particular, intracellular targets that are considered undruggable by current drug formats, such as antibodies or small chemicals.
Disease:
Details: * On December 14, 2015, Complix, a biopharmaceutical company developing a pipeline of transformative protein therapeutics, called Alphabodies™, for the treatment of cancer and severe autoimmune diseases, announced that it is advancing the development of CMX-02, a potential treatment of severe autoimmune disease. The Company has entered into an agreement with Switzerland-based Selexis SA to enable the production of this novel drug candidate. Under the agreement, Complix will have access to the Selexis SUREtechnology Platform™ for the production of high-expressing and stable clonal cell lines for use in the development and commercial manufacturing of CMX-02. Complix expects to move more rapidly towards the clinical development of CMX-02 as a result of this deal.
Financial terms:
Latest news:
